Ferroquine as Next-Generation Antimalarial: Pharmacology, Resistance Profiles, and Clinical Development
Muhindo Edgar
Department of Pharmacy Kampala International University Uganda
Email: edgar.muhindo@studwc.kiu.ac.ug
ABSTRACT
Malaria remained a global health crisis, with increasing resistance to conventional antimalarials including chloroquine and artemisinin derivatives, threatening disease control efforts. Ferroquine, a ferrocene-containing derivative of chloroquine, represents an innovative organometallic approach to antimalarial drug development designed to overcome resistance mechanisms while maintaining efficacy against chloroquine-resistant Plasmodium falciparum strains. This review evaluated the pharmacological properties of ferroquine, examined its activity against resistant parasite strains, assessed clinical development progress, and analyzed its potential role in future malaria treatment strategies. A comprehensive literature search of peer-reviewed journals, clinical trial registries, and regulatory documents published between 2010 and 2025 was conducted, focusing on ferroquine pharmacology, mechanism of action, resistance profiles, preclinical studies, and clinical trial outcomes. Ferroquine demonstrated potent activity against chloroquine-resistant and multidrug-resistant Plasmodium strains through mechanisms involving enhanced lipophilicity, altered accumulation kinetics, and potential redox-mediated parasite toxicity. Pharmacokinetic studies revealed extended half-life and favorable tissue distribution compared to parent chloroquine compound. Phase II clinical trials combining ferroquine with artesunate showed excellent efficacy and safety profiles, achieving cure rates exceeding 95 percent in African populations. However, phase III development encountered regulatory challenges, and the compound has not yet achieved market approval despite promising clinical data. Resistance development appears slower than with conventional quinolines, though specific resistance markers require further characterization. Ferroquine represented a scientifically innovative antimalarial with substantial clinical potential, yet translational challenges highlight the complex pathway from molecular innovation to therapeutic deployment in resource-limited endemic settings.
Keywords: Ferroquine, Organometallic drugs, Chloroquine resistance, Plasmodium falciparum, Antimalarial pharmacology.
CITE AS: Muhindo Edgar (2026). Ferroquine as Next-Generation Antimalarial: Pharmacology, Resistance Profiles, and Clinical Development. IAA Journal of Biological Sciences 14(1):1-7.